Emerging Cardioprotective Strategies Beyond Dexrazoxane: SGLT2 Inhibitors, Drug Repurposing, and Mitochondrial Approaches in Doxorubicin Cardiotoxicity

Doxorubicin (DOX) remains a foundation of cancer treatment; however, its clinical utility is seriously restricted by measurements of subordinate and frequently irreversible cardiotoxicity. In spite of the fact that dexrazoxane is as of now the as it were affirmed cardioprotective specialist, its limited viability and clinical restrictions highlight the require for elective methodologies. Developing prove shows that DOX-induced cardiotoxicity could be a systems-level clutter driven essentially by mitochondrial brokenness, metabolic resoluteness, disabled quality control, and controlled cell passing pathways. This audit fundamentally looks at rising cardioprotective methodologies past dexrazoxane, with a center on sodium glucose cotransporter 2 (SGLT2) inhibitors, medicate repurposing approaches, and mitochondrial-targeted treatments. We synthesize unthinking bits of knowledge and translational prove to compare these techniques in terms of robotic breadth and clinical status. SGLT2 inhibitors rise as the most clinically developed and robotically integrator choice, though repurposed drugs and mitochondrial-directed mediations offer complementary but variable potential. Finally, we highlight future bearings emphasizing combination treatments and accuracy cardioprotection to realize solid cardiac conservation in anthracycline-treated patients.